RotaTeq is a live, oral vaccine that protects infants against rotavirus, the leading cause of severe diarrhea and vomiting in young children worldwide. It contains five weakened strains of rotavirus and is given as a liquid by mouth in three doses during the first eight months of life. In high-income countries, clinical trials showed it was 85% to 98% effective at preventing severe rotavirus illness.
How RotaTeq Works
RotaTeq uses what are called “reassortant” viruses, laboratory-made combinations of human and cow rotavirus strains. These hybrid viruses are weakened enough that they can’t cause full-blown illness, but they still replicate in the lining of the small intestine, which is the same place natural rotavirus attacks. That replication triggers the immune system to build defenses right where they’re needed most.
The vaccine covers five rotavirus types: G1, G2, G3, G4, and P1A[8]. Together, these account for the majority of rotavirus strains that circulate and cause disease. After vaccination, the body produces antibodies (particularly a type called IgA) in the gut itself. This local immune response is the most important marker of protection against future rotavirus infection.
Dosing Schedule and Age Limits
RotaTeq is a three-dose series given at 2 months, 4 months, and 6 months of age. Each dose is a ready-to-use 2 mL liquid squeezed into the infant’s mouth. There are strict age windows: the first dose must be given before 15 weeks of age (14 weeks and 6 days is the hard cutoff), and all three doses must be completed before the child turns 8 months old. If an infant ages out of the window, the series cannot be started or finished late.
These age limits exist because the small risk of a serious side effect (discussed below) increases in older infants. If your baby spits out or vomits the dose, a replacement dose is not given. The vaccine is considered administered regardless.
How Effective Is It?
In clinical trials conducted in higher-income countries, RotaTeq demonstrated 85% to 98% efficacy against severe rotavirus gastroenteritis. That translates to a dramatic drop in emergency room visits and hospitalizations for rotavirus-related diarrhea.
In lower-income countries with higher baseline rates of diarrheal disease, efficacy has been more moderate, ranging from 39% to 61%. Even at those levels, the impact is substantial. Across 29 African countries that introduced rotavirus vaccination, an estimated 134,714 hospitalizations and nearly 21,000 deaths were prevented in a single year (2016), representing a 47% reduction in hospitalizations and a 39% reduction in deaths compared to pre-vaccination levels.
Common Side Effects
Most infants tolerate RotaTeq well. The most common side effects are irritability, mild temporary diarrhea, and occasional vomiting. These are typically short-lived and resolve on their own.
The rare but serious concern is intussusception, a condition where one section of the intestine slides into the next section like a telescope, causing a blockage. The estimated risk is roughly 1 in 20,000 to 1 in 100,000 vaccinated infants within the first week after a dose. In practical terms, that means between 40 and 120 U.S. infants per year might develop intussusception related to the vaccine. Signs to watch for include sudden, intense crying (often with the knees pulled up), vomiting, bloody stool, and unusual lethargy in the days following vaccination.
Who Should Not Get RotaTeq
Three groups of infants should not receive the vaccine. First, any infant who had a severe allergic reaction (such as anaphylaxis) after a previous dose or to any component of the vaccine. Second, infants diagnosed with severe combined immunodeficiency (SCID), a rare condition where the immune system is essentially nonfunctional. Because RotaTeq contains live virus, it could cause actual disease in these babies. Third, any infant with a history of intussusception, since the vaccine carries a small additional risk of that condition recurring.
RotaTeq vs. Rotarix
Two rotavirus vaccines are available. RotaTeq (made by Merck) requires three doses and contains five virus strains (G1, G2, G3, G4, and P1A[8]). Rotarix (made by GSK) requires only two doses and contains a single human rotavirus strain, G1P[8], but provides cross-protection against G3, G4, and G9 types as well.
Both vaccines have similar overall effectiveness, and either one is considered a good choice. The main practical difference is dose count: two visits versus three. If an infant starts the series with one brand and that brand isn’t available for later doses, the CDC recommends completing a total of three doses to ensure full protection, regardless of which vaccine was used first.
Storage Requirements
RotaTeq must be refrigerated between 2°C and 8°C (36°F to 46°F) and protected from light. It should never be frozen. These storage requirements matter mostly for healthcare providers and pharmacies, but they’re worth knowing if you ever notice a vaccine being administered from a vial that wasn’t properly stored.